FDA approves once-weekly efanesoctocog alfa, a new class of high-sustained factor VIII therapy for haemophilia A: Swedish Orphan Biovitrum AB

STOCKHOLM, Feb. 24, 2023 -- (Healthcare Sales & Marketing Network) -- Sobi® today announced that the US Food and Drug Administration (FDA) has approved efanesoctocog alfa [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl], a first-... Biopharmaceuticals, FDA Swedish Orphan Biovitrum, efanesoctocog alfa, factor VIII, haemophilia A
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news